Monitoring and Managing Adverse Events With IDH Inhibitors

Panelists discuss how to implement hepatotoxicity monitoring protocols, counsel patients about avoiding hepatotoxic substances, and manage the infrequent but manageable liver enzyme elevations that typically occur within the first 6 months of treatment.